X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-06 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale | $41.93 | -5,000 | 86,344 | -5% | -$209,646 | ||||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Chief Commercial Officer | S - Sale+OE | $44.06 | -130,807 | 55,000 | -70% | -$5,763,697 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Wilson Troy Edward | Dir | S - Sale+OE | $45.00 | -95,054 | 712,390 | -12% | -$4,277,430 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $47.62 | -107,500 | 173,522 | -38% | -$5,118,881 | |||||
| D | 2025-08-06 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $42.74 | -81,434 | 38,867 | -68% | -$3,480,269 | |||||
2025-08-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.32 | +675,000 | 248,372,576 | 0% | +$891,000 | ||||||
| D | 2025-08-07 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $58.00 | -10,000 | 2,426 | -80% | -$580,000 | |||||
| D | 2025-08-07 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $55.25 | -40,000 | 347,211 | -10% | -$2,210,040 | |||||
| D | 2025-08-06 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $42.02 | -140,000 | 2,075,533 | -6% | -$5,883,360 | |||||
| D | 2025-08-06 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $32.55 | -29,325 | 57,403 | -34% | -$954,529 | |||||
| D | 2025-08-07 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.00 | -11,000 | 36,781 | -23% | -$3,299,981 | |||||
| D | 2025-08-07 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $74.85 | -5,500 | 60,956 | -8% | -$411,675 | |||||
2025-08-08 | LLY | Eli Lilly & Co | Jackson Jamere | Dir | P - Purchase | $639.56 | +200 | 9,402 | +2% | +$127,913 | ||||||
2025-08-07 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | P - Purchase | $4.15 | +10,000 | 2,335,731 | 0% | +$41,500 | ||||||
2025-08-07 | GOVX | Geovax Labs, Inc. | McKee Kelly T. Jr. | Chief Medical Officer | P - Purchase | $0.67 | +1,107 | 3,494 | +46% | +$742 | ||||||
2025-08-08 | PRGO | Perrigo Co Plc | Lockwood-Taylor Patrick | CEO | P - Purchase | $22.37 | +4,460 | 85,812 | +5% | +$99,766 | ||||||
2025-08-05 | WVE | Wave Life Sciences Ltd. | Takanashi Ken | Dir | S - Sale | $8.75 | -4,872 | 5,716,303 | 0% | -$42,630 | ||||||
2025-08-05 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Dir | S - Sale | $8.75 | -1,127 | 14,988 | -7% | -$9,861 | ||||||
| D | 2025-08-05 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $71.77 | -14 | 5,487 | 0% | -$1,005 | |||||
2025-08-05 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $60.95 | -395 | 1,096,631 | 0% | -$24,075 | ||||||
2025-08-05 | ABBV | Abbvie Inc. | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT OFFICER | S - Sale | $198.51 | -13,295 | 58,247 | -19% | -$2,639,253 | ||||||
| D | 2025-08-05 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $49.00 | -17,167 | 18,589 | -48% | -$841,183 | |||||
| D | 2025-08-05 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $33.20 | -138,614 | 49,915 | -74% | -$4,602,370 | |||||
2025-08-05 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $20.00 | -30,000 | 376,412 | -7% | -$600,132 | ||||||
2025-08-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | P - Purchase | $389.58 | +10,000 | 115,968 | +9% | +$3,895,768 | ||||||
2025-08-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachs Bruce I | Dir | P - Purchase | $389.68 | +5,000 | 45,000 | +13% | +$1,948,416 | ||||||
| M | 2025-08-05 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $2.77 | -31,191 | 1,048,912 | -3% | -$86,250 | |||||
| D | 2025-08-05 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $49.30 | -12,500 | 167,124 | -7% | -$616,299 | |||||
2025-08-06 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.81 | -1,332 | 442,507 | 0% | -$7,739 | ||||||
2025-08-05 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale | $42.86 | -10,000 | 89,492 | -10% | -$428,593 | ||||||
| D | 2025-08-04 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.17 | -5,500 | 0 | -100% | -$28,435 | |||||
| D | 2025-08-04 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $32.89 | -18,889 | 27,009 | -41% | -$621,259 | |||||
| D | 2025-08-04 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $32.35 | -17,000 | 33,041 | -34% | -$549,950 | |||||
| D | 2025-08-04 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $109.81 | -6,830 | 588,335 | -1% | -$750,008 | |||||
| D | 2025-08-04 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $109.50 | -8,715 | 83,111 | -9% | -$954,293 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Cunningham Kenneth | Dir | S - Sale+OE | $13.14 | -10,808 | 79,776 | -12% | -$142,057 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Deschamps Lisa | Dir | S - Sale+OE | $13.14 | -9,464 | 84,856 | -10% | -$124,392 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Fisher Andrew | GC | S - Sale+OE | $13.14 | -9,584 | 417,903 | -2% | -$125,969 | |||||
2025-08-05 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $51.74 | -10,739 | 337,767 | -3% | -$555,636 | ||||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale+OE | $13.14 | -208,912 | 12,464,968 | -2% | -$2,745,877 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale+OE | $13.14 | -58,336 | 2,607,472 | -2% | -$766,751 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Ackermann Christina | Dir | S - Sale+OE | $13.14 | -1,808 | 64,072 | -3% | -$23,764 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Austwick Michael | Dir | S - Sale+OE | $13.14 | -11,288 | 12,712 | -47% | -$148,366 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Brady James Aloysius | Dir | S - Sale+OE | $13.14 | -824 | 23,176 | -3% | -$10,830 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale+OE | $13.14 | -208,912 | 13,376,144 | -2% | -$2,745,877 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Ebsworth David R | Dir | S - Sale+OE | $13.14 | -1,904 | 1,498,099 | 0% | -$25,026 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Edwards Martin | Dir | S - Sale+OE | $13.14 | -10,808 | 157,992 | -6% | -$142,057 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Shah Mahendra | Dir | S - Sale+OE | $13.14 | -3,608 | 93,472 | -4% | -$47,422 | |||||
| D | 2025-08-01 | VRNA | Verona Pharma Plc | Sinha Vikas | Dir | S - Sale+OE | $13.14 | -4,328 | 94,112 | -4% | -$56,886 | |||||
| D | 2025-08-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $67.79 | -35,007 | 57,681 | -38% | -$2,373,237 | |||||
2025-08-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $68.53 | -40,000 | 2,861,370 | -1% | -$2,741,207 | ||||||
| D | 2025-08-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $67.51 | -5,823 | 10,066 | -37% | -$393,128 | |||||
2025-08-04 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $14.33 | -11,547 | 1,134,703 | -1% | -$165,429 | ||||||
2025-08-04 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $14.33 | -2,622 | 112,846 | -2% | -$37,564 | ||||||
2025-08-04 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP CFO | S - Sale | $14.33 | -89 | 65,015 | 0% | -$1,275 | ||||||
| D | 2025-08-05 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $36.34 | -2,000 | 140,610 | -1% | -$72,680 | |||||
2025-08-04 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $14.33 | -6,330 | 197,364 | -3% | -$90,687 | ||||||
| D | 2025-08-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $14.30 | -10,000 | 100,206 | -9% | -$142,982 | |||||
| D | 2025-08-02 | BMY | Bristol Myers Squibb Co | Short Bartie Wendy | EVP, Corporate Affairs | S - Sale+OE | $44.23 | -378 | 5,066 | -7% | -$16,719 | |||||
| M | 2025-08-01 | AUPH | Aurinia Pharmaceuticals Inc. | Tang Kevin | Dir | P - Purchase | $10.45 | +1,300,000 | 11,329,500 | +13% | +$13,590,000 | |||||
2025-08-04 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale | $42.80 | -9,549 | 51,507 | -16% | -$408,701 | ||||||
2025-08-04 | RNA | Avidity Biosciences, Inc. | Moriarty John B | GC | S - Sale | $36.21 | -2,245 | 47,755 | -4% | -$81,291 | ||||||
2025-08-01 | ONC | Beone Medicines Ltd. | Rosenberg Aaron | CFO | S - Sale | $290.47 | -1,190 | 215,332 | -1% | -$345,659 | ||||||
2025-08-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $131.88 | -467 | 45,989 | -1% | -$61,586 | ||||||
2025-08-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $113.21 | -1,000 | 435,973 | 0% | -$113,210 | ||||||
2025-08-01 | AUPH | Aurinia Pharmaceuticals Inc. | Keenan Greg | Chief Medical Officer | S - Sale | $10.50 | -20,000 | 133,484 | -13% | -$210,000 | ||||||
2025-08-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $12.82 | -4,504 | 16,775 | -21% | -$57,724 | ||||||
| D | 2025-08-01 | TEVA | Teva Pharmaceutical Industries Ltd | Jover Placid | See "Remarks" | S - Sale+OE | $15.16 | -6,053 | 6,774 | -47% | -$91,748 | |||||
| D | 2025-08-01 | TEVA | Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "Remarks" | S - Sale+OE | $15.16 | -52,742 | 0 | -100% | -$799,437 | |||||
2025-07-30 | CYCC | Cyclacel Pharmaceuticals, Inc. | Lazar David E. | 10% | S - Sale | $12.36 | -6,750 | 155,838 | -4% | -$83,430 | ||||||
2025-08-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $20.83 | -500 | 77,031 | -1% | -$10,416 | ||||||
2025-07-31 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | * Director by Deputization, 10% | P - Purchase | $3.20 | +9,375,000 | 30,606,974 | +44% | +$30,000,000 | ||||||
2025-07-31 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.08 | +10,000 | 953,334 | +1% | +$30,800 | ||||||
2025-08-01 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $11.03 | -5,402 | 35,512 | -13% | -$59,598 | ||||||
2025-07-30 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $61.04 | -8,492 | 1,097,026 | -1% | -$518,352 | ||||||
2025-07-30 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $2.43 | +4,115 | 33,830 | +14% | +$9,999 | ||||||
| DM | 2025-07-30 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir, 10% | S - Sale+OE | $2.28 | -129,449 | 21,232 | -86% | -$295,532 | |||||
| D | 2025-07-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $80.36 | -4,000 | 48,034 | -8% | -$321,440 | |||||
| D | 2025-07-30 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $45.00 | -2,432 | 179,820 | -1% | -$109,440 | |||||
| M | 2025-07-29 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $302.65 | -4,300 | 1,690,494 | 0% | -$1,301,375 | |||||
2025-07-30 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $304.60 | -920 | 266,474 | 0% | -$280,233 | ||||||
2025-07-29 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $36.45 | -5,000 | 392,274 | -1% | -$182,250 | ||||||
2025-07-30 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.16 | +5,000 | 579,925 | +1% | +$15,800 | ||||||
| M | 2025-07-28 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $14.62 | -73,678 | 132,934 | -36% | -$1,077,477 | |||||
| D | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $12.01 | -4,304 | 40,914 | -10% | -$51,695 | |||||
| D | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $12.01 | -3,841 | 44,009 | -8% | -$46,134 | |||||
| D | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $12.01 | -4,308 | 69,023 | -6% | -$51,743 | |||||
| D | 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.46 | -3,250 | 23,000 | -12% | -$66,504 | |||||
| DM | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | Bunka Christopher | Dir | P - Purchase | $0.92 | +27,500 | 909,867 | +3% | +$25,241 | |||||
2025-07-29 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale | $15.23 | -8,322 | 208,163 | -4% | -$126,751 | ||||||
2025-07-29 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $4.37 | -191 | 27,223 | -1% | -$835 | ||||||
2025-07-28 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $19.54 | -454 | 193,180 | 0% | -$8,871 | ||||||
2025-07-28 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $19.54 | -1,063 | 186,105 | -1% | -$20,771 | ||||||
2025-07-28 | URGN | Urogen Pharma Ltd. | Smith Jason Drew | GC | S - Sale | $19.14 | -7,522 | 41,492 | -15% | -$143,971 | ||||||
2025-07-28 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $19.14 | -5,149 | 158,229 | -3% | -$98,552 | ||||||
| D | 2025-07-29 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $6.50 | -4,196 | 0 | -100% | -$27,274 | |||||
| D | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | McKechnie William Edward | Dir | P - Purchase | $0.91 | +5,000 | 31,382 | +19% | +$4,532 | |||||
| D | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | Docherty John Martin | Pres, CSO | P - Purchase | $0.93 | +5,376 | 59,451 | +10% | +$4,989 | |||||
| D | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | Carle Vanessa | Secretary | P - Purchase | $0.91 | +750 | 750 | New | +$683 | |||||
| D | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | Christopher Richard | CEO | P - Purchase | $0.91 | +15,000 | 115,000 | +15% | +$13,641 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |